SOTIO is a biotechnology company that is developing new Active Cellular Immunotherapy (ACI).
The company focuses on the treatment of cancer and immune system mediated diseases. SOTIO conducts a research of its own platform of ACI based on dendritic cells, as well as its clinical testing in order to launch new medicine into the market. The company develops new medicine, marked as DCVAC/PCa for prostate cancer patients. In 2012, SOTIO launched “Phase II” clinical trials, involving hundreds of patients. Futher goal is to verify the drug’s safety and efficacy in a Phase III VIABLE global clinical trial which commended in 2014 and would include 1,170 patients.
In 2013, the company started clinical trials of ACI in the treatment of cancer of the ovaries (the DCVAC/OvCa drug) which take place in the Czech Republic, Germany and Poland. A research focused on ACI for lung cancer treatment (the DCVAC/LuCa) is still in its early stage. The company is also looking for other opportunities to further expand its product portfolio.
In 2011, SOTIO has built its own cell therapy manufacturing and research facility in Prague which is among the most modern in Europe. These super clean laboratories meet the most stringent requirements for the sterile production of the drugs used in cellular therapy. Similar laboratories were open in 2014 in Bejjing.
SOTIO is headquartered in Prague, the Czech Republic, and has active presence also in the U.S., Russia and China, employing over 260 professionals (as at June 30, 2014).
SOTIO is a part of PPF Group as of the end of the year 2012.
SOTIO N.V.: Management as at June 1, 2015
|Board of Directors||Mr. Marcel Marinus van Santen, Director|
|Jan Cornelis Jansen, Director|
170 00 Prague 7
The Czech Republic
Phone: +420 224 175 111
1077 XX Amsterdam